<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "10: compliance with", fill: "#fefe33"},
{source: "10: compliance with", target: "10: minimum bid price requirement", fill: "#fefe33"},
{source: "10: minimum bid price requirement", target: "10: Nasdaq Capital Market", fill: "#fefe33"},
{source: "10: compliance with", target: "19: compliance with", fill: "#4166f5"},
{source: "19: compliance with", target: "19: stockholders equity requirement", fill: "#4166f5"},
{source: "19: stockholders equity requirement", target: "19: must either raise additional funds", fill: "#4166f5"},
{source: "19: must either raise additional funds", target: "19: debt securities", fill: "#4166f5"},
{source: "19: debt securities", target: "19: markets sell certain", fill: "#4166f5"},
{source: "19: markets sell certain", target: "19: otherwise increase stockholders", fill: "#4166f5"},
{source: "19: otherwise increase stockholders", target: "19: equity through operations", fill: "#4166f5"},
{source: "19: compliance with", target: "30: same manner", fill: "#f0dc82"},
{source: "30: same manner", target: "30: done prior", fill: "#f0dc82"},
{source: "30: done prior", target: "30: stockholders equity", fill: "#f0dc82"},
{source: "30: stockholders equity", target: "30: example by selling", fill: "#f0dc82"},
{source: "30: example by selling", target: "30: requirement", fill: "#f0dc82"},
{source: "30: requirement", target: "30: stock will once", fill: "#f0dc82"},
{source: "30: same manner", target: "32: significant revenues", fill: "#e32636"},
{source: "32: significant revenues", target: "32: profitability", fill: "#e32636"},
{source: "32: significant revenues", target: "39: significant revenues from", fill: "#f78fa7"},
{source: "39: significant revenues from", target: "39: product sales", fill: "#f78fa7"},
{source: "39: product sales", target: "39: incur significant", fill: "#f78fa7"},
{source: "39: incur significant", target: "39: net losses over", fill: "#f78fa7"},
{source: "39: net losses over", target: "39: next several years", fill: "#f78fa7"},
{source: "39: next several years", target: "39: losses may increase", fill: "#f78fa7"},
{source: "39: significant revenues from", target: "42: recently implemented", fill: "#663854"},
{source: "42: recently implemented", target: "42: restructuring initiative primarily", fill: "#663854"},
{source: "42: restructuring initiative primarily", target: "42: manufacturing", fill: "#663854"},
{source: "42: recently implemented", target: "47: single contract manufacturer", fill: "#a4dded"},
{source: "47: single contract manufacturer", target: "47: manufacture", fill: "#a4dded"},
{source: "47: single contract manufacturer", target: "69: Physicians ", fill: "#ae0c00"},
{source: "69: Physicians ", target: "69: health care providers", fill: "#ae0c00"},
{source: "69: health care providers", target: "69: adequately reimbursed", fill: "#ae0c00"},
{source: "69: adequately reimbursed", target: "69: Stretta ", fill: "#ae0c00"},
{source: "69: Physicians ", target: "76: procedure effective either from", fill: "#008b8b"},
{source: "76: procedure effective either from", target: "76: depending upon", fill: "#008b8b"},
{source: "76: depending upon", target: "76: necessary preconditions", fill: "#008b8b"},
{source: "76: necessary preconditions", target: "76: cannot assure", fill: "#008b8b"},
{source: "76: cannot assure", target: "76: procedure will ever", fill: "#008b8b"},
{source: "76: procedure will ever", target: "76: event there", fill: "#008b8b"},
{source: "76: event there", target: "76: reimbursement", fill: "#008b8b"},
{source: "76: reimbursement", target: "76: such reimbursement will", fill: "#008b8b"},
{source: "76: procedure effective either from", target: "120: significant risks involved", fill: "#0067a5"},
{source: "120: significant risks involved", target: "120: Inability ", fill: "#0067a5"},
{source: "120: Inability ", target: "120: acceptance", fill: "#0067a5"},
{source: "120: acceptance", target: "120: technology", fill: "#0067a5"},
{source: "120: technology", target: "120: effectively", fill: "#0067a5"},
{source: "120: effectively", target: "120: adequately", fill: "#0067a5"},
{source: "120: adequately", target: "120: them less effective promoters", fill: "#0067a5"},
{source: "120: them less effective promoters", target: "120: in the Failure ", fill: "#0067a5"},
{source: "120: in the Failure ", target: "120: accurately", fill: "#0067a5"},
{source: "120: accurately", target: "120: alternatives", fill: "#0067a5"},
{source: "120: alternatives", target: "120: conventional", fill: "#0067a5"},
{source: "120: conventional", target: "120: treatments", fill: "#0067a5"},
{source: "120: significant risks involved", target: "171: addition contracts may", fill: "#746cc0"},
{source: "171: addition contracts may", target: "171: difficult", fill: "#746cc0"},
{source: "171: difficult", target: "171: receivables difficult", fill: "#746cc0"},
{source: "171: receivables difficult", target: "171: collect through", fill: "#746cc0"},
{source: "171: collect through", target: "171: foreign countrys legal system", fill: "#746cc0"},
{source: "171: foreign countrys legal system", target: "171: intellectual property", fill: "#746cc0"},
{source: "171: intellectual property", target: "171: foreign countries may", fill: "#746cc0"},
{source: "171: addition contracts may", target: "START_HERE", fill: "#746cc0"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Formally complain</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sales">Sales</a></td>
      <td>Wales (Welsh: Cymru [ˈkəm.rɨ] (listen)) is a country that is part of the United Kingdom. It is bordered by England to the east, the Severn Estuary to the south-east, the Bristol Channel to the south, the Celtic sea to the south-west and the Irish Sea to the west and north.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_(economics)">Profit (economics)</a></td>
      <td>An economic profit is the difference between the revenue a  commercial entity has received from its outputs and the opportunity costs of its inputs. It equals to total revenue minus total cost, including both explicit and implicit costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_analysis">Profitability analysis</a></td>
      <td>In cost accounting, profitability analysis is an analysis of the profitability of an organisation's output. Output of an organisation can be grouped into products, customers, locations, channels and/or transactions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_Profitability_Analysis">Customer Profitability Analysis</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Small_Is_Profitable">Small Is Profitable</a></td>
      <td>Small Is Profitable: The Hidden Economic Benefits of Making Electrical Resources the Right Size is a 2002 book by energy analyst Amory Lovins and others.  The book describes 207 ways in which the size of "electrical resources"—devices that make, save, or store electricity—affects their economic value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SAP_ERP">SAP ERP</a></td>
      <td>SAP ERP is an enterprise resource planning software developed by the German company SAP SE. SAP ERP incorporates the key business functions of an organization. The latest version of SAP ERP (V.6.0) was made available in 2006.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Net_income">Net income</a></td>
      <td>In business and accounting, net income (also total comprehensive income, net earnings, net profit, bottom line, sales profit, or credit sales) is an entity's income minus cost of goods sold, expenses, depreciation and amortization, interest, and taxes for an accounting period.It is computed as the residual of all revenues and gains less all expenses and losses for the period, and has also been defined as the net increase in shareholders' equity that results from a company's operations. It is different from gross income, which only deducts the cost of goods sold from revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sales_promotion">Sales promotion</a></td>
      <td>Sales promotion is one of the elements of the promotional mix. The primary elements in the promotional mix are advertising, personal selling, direct marketing and publicity/public relations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porcelain_manufacturing_companies_in_Europe">Porcelain manufacturing companies in Europe</a></td>
      <td>Porcelain manufacturing companies are firms which manufacture porcelain.\n\n\n== European porcelain manufacturers before the 18th century ==\nThe table below lists European manufacturers of porcelain established before the 18th century.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gastroesophageal_reflux_disease">Gastroesophageal reflux disease</a></td>
      <td>Gastroesophageal reflux disease (GERD) or gastro-oesophageal reflux disease (GORD) is a chronic condition in which stomach contents and acid rise up into the esophagus, resulting in symptoms and/or complications. Symptoms include the taste of acid in the back of the mouth, heartburn, bad breath, chest pain, regurgitation, breathing problems, and wearing away of the teeth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alisher_Usmanov">Alisher Usmanov</a></td>
      <td>Alisher Burkhanovich Usmanov (Russian: Алишер Бурханович Усманов; born 9 September 1953) is an Uzbek-born Russian businessman and oligarch. By 2022, Usmanov had an estimated net worth of $19.5 billion and was among the world's 100 wealthiest people.Usmanov made his wealth after the collapse of the Soviet Union, through metal and mining operations, and investments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2011_military_intervention_in_Libya">2011 military intervention in Libya</a></td>
      <td>On 19 March 2011, a multi-state NATO-led coalition began a military intervention in Libya, to implement United Nations Security Council Resolution 1973, in response to events during the First Libyan Civil War. With ten votes in favour and five abstentions, the UN Security Council's intent was to have "an immediate ceasefire in Libya, including an end to the current attacks against civilians, which it said might constitute "crimes against humanity" ...</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tourism_in_Abkhazia">Tourism in Abkhazia</a></td>
      <td>Tourism in Abkhazia is possible under Georgian law for foreigners entering the occupied territory from Georgia, although Georgia cannot assure the safety inside disputed territory.\nHowever, the Abkazian beaches on the Black Sea continue to be accessible for tourists coming from the Russian side of the Abkhazia–Russia border which is not under Georgian control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/What's_Your_Raashee?">What's Your Raashee?</a></td>
      <td>What's Your Raashee? (lit. 'What's Your Zodiac Sign?') is a 2009 Indian Hindi-language romantic comedy film written and directed by Ashutosh Gowariker.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Synchroscope">Synchroscope</a></td>
      <td>In AC electrical power systems, a synchroscope is a device that indicates the degree to which two systems (generators or power networks) are synchronized with each other.For two electrical systems to be synchronized, both systems must operate at the same frequency, and the phase angle between the systems must be zero (and two polyphase systems must have the same phase sequence). Synchroscopes measure and display the frequency difference and phase angle between two power systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CURON MEDICAL INC      Item 1A     Risk Factors        We have limited <font color="blue">capital resources</font> and we will need to <font color="blue">raise <font color="blue">additional</font> funds</font>     if we want to continue our <font color="blue">current level</font> of <font color="blue">operations</font>, which we may not be     able to do</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we had cash and <font color="blue">cash equivalents on hand</font> of dlra3dtta3     million and working capital of dlra4dtta1 million</td>
    </tr>
    <tr>
      <td>To <font color="blue">continue <font color="blue">operations</font></font>, we must     <font color="blue">raise <font color="blue">additional</font> funds</font> through the issuance of equity or <font color="blue">debt securities</font> in     the public or <font color="blue">private markets</font>, or <font color="blue">sell certain</font> of our assets</td>
    </tr>
    <tr>
      <td>No assurance     can be given that we will be successful in obtaining <font color="blue">funds from</font> any of these     <font color="blue">transactions</font>  on acceptable terms, if at all, or if secured, that such     <font color="blue">funding would</font> be sufficient to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">future equity</font>     <font color="blue">financing could</font> result in substantial dilution to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we     <font color="blue">raise <font color="blue">additional</font> funds</font> by issuing debt, we may be subject to <font color="blue">limitations on</font>     our <font color="blue">operations</font>, through debt covenants or other <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>In the absence     of funding, we will be required to scale back or terminate <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We     believe  that our <font color="blue">cash balances will</font> not be sufficient to fund planned     <font color="blue">expenditures</font> in the <font color="blue">third quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>This raises substantial doubt     about our ability to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>We are not in <font color="blue">compliance with</font> the <font color="blue"><font color="blue">minimum bid price</font> <font color="blue">requirement</font></font> of the     <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may consequently</font> be delisted in the near future</td>
    </tr>
    <tr>
      <td>This <font color="blue">may <font color="blue">adversely</font> affect trading</font> in our stock and our ability to raise     capital</td>
    </tr>
    <tr>
      <td>We  have  failed  to <font color="blue">comply with</font> the minimum dlra1dtta00 per share bid price     <font color="blue">requirement</font> for <font color="blue">continued listing</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Nasdaq </font>staff has <font color="blue">notified us</font> that we     have until May 11, 2006 to demonstrate <font color="blue">compliance with</font> the <font color="blue">minimum bid price</font>     <font color="blue">requirement</font>, or the Nasdaq <font color="blue">staff will provide notification</font> that our stock     will be delisted</td>
    </tr>
    <tr>
      <td>To  achieve  compliance  with  the  <font color="blue"><font color="blue">minimum bid price</font> <font color="blue">requirement</font></font>, our     <font color="blue">stockholders</font> have <font color="blue">authorized up</font> to a 1-for-4 <font color="blue">reverse stock split</font> on our     stock</td>
    </tr>
    <tr>
      <td>Should we implement a <font color="blue">reverse stock split</font>, the number of our shares     being <font color="blue">traded will</font> be reduced and <font color="blue">volatility</font> in the trading of our stock may     increase</td>
    </tr>
    <tr>
      <td>Further, there are <font color="blue">no assurances</font> that a <font color="blue">reverse stock split</font> will     ensure <font color="blue">compliance with</font> the <font color="blue"><font color="blue">minimum bid price</font> <font color="blue">requirement</font></font></td>
    </tr>
    <tr>
      <td>There are also no     assurances that our stock price after a <font color="blue">reverse stock split</font> will be above     dlra1dtta00 per share at all (<font color="blue">which would</font> be the case if, prior to the split, our     stock price is below dlra0dtta25 per share), nor that it will maintain a dlra1dtta00 per     share price for at least ten consecutive trading days—the <font color="blue">requirement</font> to     remedy the <font color="blue">minimum bid price</font> <font color="blue">deficiency</font></td>
    </tr>
    <tr>
      <td>To achieve <font color="blue">compliance with</font> the     <font color="blue">stockholders</font>’ equity <font color="blue">requirement</font>, we must either <font color="blue">raise <font color="blue">additional</font> funds</font>     through the issuance of equity or <font color="blue">debt securities</font> in the public or private     markets, <font color="blue">sell certain</font> of our assets, or otherwise increase <font color="blue">stockholders</font>’     equity through <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we receive a notice of delisting, we may appeal the <font color="blue">decision but there</font>     are <font color="blue">no assurances</font> that we will be successful in <font color="blue">remaining listed</font></td>
    </tr>
    <tr>
      <td>If we are     ultimately delisted, trading in our <font color="blue"><font color="blue">common stock</font> could</font> be subject to the     so-called “penny stock” rules that <font color="blue">impose <font color="blue">additional</font> sales practice</font> and     market making <font color="blue">requirement</font>s on broker-dealers who sell and/or make a market     in those securities</td>
    </tr>
    <tr>
      <td>Consequently, <font color="blue">removal from</font> the <font color="blue">Nasdaq Capital Market</font>,     if  it  were  to  occur,  could  affect  the ability or <font color="blue">willingness</font> of     broker-dealers to sell and/or make a <font color="blue">market on</font> our <font color="blue">common stock</font> and the     ability of purchasers of our <font color="blue">common stock</font> to sell their securities in the     <font color="blue">secondary market</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">rules could further limit</font> the <font color="blue">market liquidity</font> of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">delisted from</font> the <font color="blue">Nasdaq Capital Market</font>, our     stock price is likely to <font color="blue">decline <font color="blue"><font color="blue">significant</font>ly</font></font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> Nasdaq’s <font color="blue">stockholders</font>’ equity <font color="blue">requirement</font>, our     stock will be subject to delisting</td>
    </tr>
    <tr>
      <td>We  have  recently  failed  to  comply  with  the minimum dlra2dtta5 million     <font color="blue">stockholders</font>’ equity <font color="blue">requirement</font> of the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>Due to this     <font color="blue">deficiency</font>,  the  Nasdaq  staff  <font color="blue">notified us</font> that it was reviewing our     <font color="blue">eligibility</font> for <font color="blue">continued listing</font> on the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>To remedy     this <font color="blue">deficiency</font>, we <font color="blue">sold certain</font> of our <font color="blue">unutilized <font color="blue"><font color="blue">intellectual</font> property</font></font>     assets for dlra3 million to increase our <font color="blue">stockholders</font>’ equity</td>
    </tr>
    <tr>
      <td>While we believe     that our actions were sufficient to remedy our <font color="blue">deficiency</font>, there are no     assurances that our <font color="blue">stockholders</font>’ equity will remain above Nasdaq’s dlra2dtta5     <font color="blue">million minimum</font></td>
    </tr>
    <tr>
      <td>If we continue to operate our business in the <font color="blue">same manner</font>     as we had <font color="blue">done prior</font> to our sale of assets, we will either have to raise our     <font color="blue">stockholders</font> equity, for example, by selling more assets or                                           15     ______________________________________________________________________       equity, or we will fall below Nasdaq’s <font color="blue">requirement</font> and our <font color="blue">stock will once</font>     again be subject to delisting</td>
    </tr>
    <tr>
      <td>Furthermore, if we fail to <font color="blue">comply with</font> this     <font color="blue">requirement</font>  upon  the  filing of our Form 10-Q for the quarter ending     March 31, 2006, our stock will be <font color="blue">immediately delisted</font></td>
    </tr>
    <tr>
      <td>We may never achieve or maintain <font color="blue"><font color="blue">significant</font> revenues</font> or <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have only a limited operating <font color="blue">history upon which</font> you can evaluate our     business</td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred losses every year since</font> we began <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we had an     <font color="blue">accumulated deficit</font> of approximately dlra105dtta6 million</td>
    </tr>
    <tr>
      <td>Our revenues are, and     will  be,  derived  from the sale of <font color="blue">radiofrequency generators</font> and our     disposable devices, such as the <font color="blue">Stretta Catheter </font>and Secca Handpiece</td>
    </tr>
    <tr>
      <td>We     have generated limited revenues, and it is possible that we will never     <font color="blue">generate <font color="blue">significant</font> revenue from <font color="blue">product sales</font></font></td>
    </tr>
    <tr>
      <td>Even if we do achieve     <font color="blue"><font color="blue">significant</font> revenues</font> from our <font color="blue">product sales</font>, we expect to <font color="blue">incur <font color="blue">significant</font></font>     <font color="blue">net losses over</font> the <font color="blue">next several years</font> and these <font color="blue">losses may increase</font></td>
    </tr>
    <tr>
      <td>It is     possible that we will never achieve profitable <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">recently undergone</font> a restructuring, <font color="blue">which could</font> <font color="blue">adversely</font> impact our     business</td>
    </tr>
    <tr>
      <td>In order to reduce our operating costs, we have <font color="blue">recently implemented</font> a     <font color="blue">restructuring initiative primarily</font> to implement the outsourcing of our     disposable component <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>This resulted in a <font color="blue"><font color="blue">significant</font> reduction</font>     in employee headcount from 71 to 32</td>
    </tr>
    <tr>
      <td>We <font color="blue">entered into</font> a contract for the     outsourced  <font color="blue">manufacturing</font>  of  our  <font color="blue">disposable products</font></td>
    </tr>
    <tr>
      <td>These actions     <font color="blue"><font color="blue">significant</font>ly</font>  change  our  <font color="blue">operations</font> and could have adverse results,     including:           •   <font color="blue">Potential </font><font color="blue">customers may choose</font> not to purchase our <font color="blue">products due</font> to     <font color="blue">concerns over</font> the stability of our <font color="blue">organization</font>;           •   We <font color="blue">may <font color="blue">encounter <font color="blue">difficult</font>ies</font></font> in retaining <font color="blue">key employees</font>; and           •   The reduction of our operating costs may not achieve the goal of     producing <font color="blue">materially stronger financial</font> results than we have <font color="blue">historically</font>     experienced</td>
    </tr>
    <tr>
      <td>We have outsourced the <font color="blue">manufacturing</font> of our <font color="blue">disposable products</font> to a single     <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font></font>, and if that <font color="blue"><font color="blue">manufacture</font>r</font> is unable or unwilling to     produce  our  product  <font color="blue">requirement</font>s  in  quality  and  quantity to our     <font color="blue">satisfaction</font>, our business will be harmed</td>
    </tr>
    <tr>
      <td>We now rely on a single <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font></font> to <font color="blue">manufacture</font> our disposable     products</td>
    </tr>
    <tr>
      <td>We have <font color="blue">no prior history with</font> this supplier and <font color="blue">cannot predict how</font>     well they will perform in meeting our quality and quantity <font color="blue">requirement</font>s</td>
    </tr>
    <tr>
      <td>We     believe that this shift away from direct <font color="blue">manufacturing</font> will reduce our     operating  expenses,  <font color="blue">but unforeseeable <font color="blue">difficult</font>ies</font> in the outsourced     <font color="blue">manufacturing</font>  could  <font color="blue">negatively</font>  impact  operating  <font color="blue">expense reduction</font>     <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> this single <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font></font> subjects us     to a number of <font color="blue">risks outside</font> of our control that <font color="blue">could impact</font> our ability to     meet demand for our <font color="blue">disposable products</font> and harm our business, including:           •   <font color="blue">Inability </font>of our <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font></font> to <font color="blue">manufacture</font> the product at     the quality and quantity levels we require;           •   Delays or <font color="blue">interruption</font> of production due to production problems; and           •   <font color="blue">Unanticipated </font>delays in <font color="blue">delivery by</font> our <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font></font> due to     changes in <font color="blue">demand from us</font> or their other customers</td>
    </tr>
    <tr>
      <td>We have yet to identify an alternate <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font></font> to <font color="blue">manufacture</font>     our  disposable  products</td>
    </tr>
    <tr>
      <td><font color="blue">Identifying  </font>and  qualifying <font color="blue">additional</font> or     <font color="blue">replacement</font> <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font></font>s, if required, may not be accomplished     quickly  or at all and could involve <font color="blue">significant</font> <font color="blue">additional</font> costs</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">interruption</font> from our existing <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>r</font></font> would limit our ability     to <font color="blue">manufacture</font> our <font color="blue">disposable products</font> and <font color="blue">could therefore</font> have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       Our <font color="blue"><font color="blue">internal controls</font> may</font> not be sufficient to <font color="blue">ensure timely</font> and reliable     financial information</td>
    </tr>
    <tr>
      <td>We restated our financial results for the quarter ended March 31, 2004 to     <font color="blue">reflect adjustments</font> to our <font color="blue">previously</font> reported financial information</td>
    </tr>
    <tr>
      <td>The     <font color="blue"><font color="blue">restatement</font>s</font> arose, in part, out of an <font color="blue">internal <font color="blue">investigation</font> by</font> the Audit     Committee</td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">investigation</font>, <font color="blue">management</font> and the Audit     Committee determined that <font color="blue">certain sales employees</font> had <font color="blue">improperly offered</font>     rights  of return and exchange in violation of our <font color="blue">revenue recognition</font>     policy, and a <font color="blue"><font color="blue">manufacture</font>r</font>’s representative had not actually made sales that     it had reported to us</td>
    </tr>
    <tr>
      <td>As a result of this <font color="blue">investigation</font>, we were also     unable to timely file the Form 10-Q for the quarter ended June 30, 2004</td>
    </tr>
    <tr>
      <td>In     <font color="blue">connection with</font> the <font color="blue">restatement</font> of our financial results for the quarter     ended March 31, 2004, our <font color="blue">independent registered public <font color="blue">accounting</font> firm</font>     identified material <font color="blue">weaknesses</font> in our <font color="blue">internal controls</font> and procedures</td>
    </tr>
    <tr>
      <td>Our Audit Committee, with the assistance of <font color="blue">independent legal</font> and <font color="blue">accounting</font>     advisors,  evaluated  the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue"><font color="blue">disclosure</font> controls</font> and     procedures</td>
    </tr>
    <tr>
      <td>As a result of this <font color="blue">evaluation</font>, our <font color="blue">Board of Directors </font>directed     <font color="blue">management</font> to implement and <font color="blue">management</font> implemented <font color="blue">additional</font> measures     designed to ensure that information required to be disclosed in our periodic     reports is recorded, processed, summarized and reported <font color="blue">accurately</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>measures  include  the adoption of a Disclosure Committee Charter, the     adoption  of a written <font color="blue">revenue recognition</font> policy, further controls on     shipment of products for revenue <font color="blue">transactions</font>, and <font color="blue">additional</font> training of     our sales and <font color="blue">marketing staff</font> to minimize the risk of <font color="blue">revenue recognition</font>     errors</td>
    </tr>
    <tr>
      <td>Given the <font color="blue">additional</font> measures adopted by us, we believe that our     <font color="blue"><font color="blue">disclosure</font> controls</font> and procedures are now <font color="blue"><font color="blue">effective</font>ly</font> designed to ensure     that information we are required to disclose in reports that we file or     submit <font color="blue">to the SEC </font>is recorded, processed, summarized and reported within the     time <font color="blue">periods specified</font> in <font color="blue">Securities and Exchange Commission </font>rules and     forms</td>
    </tr>
    <tr>
      <td>However, the <font color="blue"><font color="blue">effective</font>ness</font> of our controls and procedures are still     limited by a variety of factors including:           •   Faulty <font color="blue">human judgment</font> and simple errors, omissions or mistakes;           •   <font color="blue">Fraudulent </font>action of an individual or collusion of two or more people;           •   <font color="blue">In<font color="blue">appropriate</font> </font><font color="blue">management</font> override of procedures; and           •   The <font color="blue">possibility</font> that our <font color="blue">enhanced controls</font> and <font color="blue">procedures may still</font>     not be adequate to <font color="blue">assure timely</font> and accurate financial information</td>
    </tr>
    <tr>
      <td>If we fail to have <font color="blue"><font color="blue">effective</font> internal control over financial</font> reporting in     place,  we  could  be  unable to <font color="blue">provide timely</font> and accurate financial     information and be subject to delisting, and civil or <font color="blue">criminal sanctions</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">health care providers</font> are not <font color="blue"><font color="blue">adequately</font> reimbursed</font> for the procedures,     in which our products are used, or for the <font color="blue">products themselves</font>, we may never     achieve <font color="blue"><font color="blue">significant</font> revenues</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">physician customers continue</font> to <font color="blue">encounter <font color="blue">difficult</font>ies</font> in readily     obtaining <font color="blue">reimbursement</font> for the Stretta <font color="blue">procedure on</font> a case-by-case basis,     and this continues to impact our ability to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>We have not     <font color="blue">been successful at addressing</font> these <font color="blue"><font color="blue">difficult</font>ies with</font> our strategies of     pursuing state-by-state and also selected national <font color="blue">reimbursement</font> coverage,     <font color="blue">focusing on promoting</font> repeat <font color="blue">catheter sales</font> and <font color="blue">incorporating technical</font>     <font color="blue">improvements</font> to our systems to <font color="blue">reduce treatment times</font></td>
    </tr>
    <tr>
      <td>Physicians,  hospitals and other <font color="blue">health care providers</font> are unlikely to     purchase our products if they are not <font color="blue"><font color="blue">adequately</font> reimbursed</font> for the <font color="blue">Stretta     </font>procedure or the products</td>
    </tr>
    <tr>
      <td>For 2006, the <font color="blue">new national payment rate</font> for the     Stretta procedure is set at dlra1cmam431dtta39</td>
    </tr>
    <tr>
      <td>This translates to a range of actual     <font color="blue">reimbursement</font> amounts, depending on the <font color="blue">geographic adjustments</font>, of between     dlra1cmam047dtta49 and dlra2cmam768dtta74</td>
    </tr>
    <tr>
      <td>Even with this amount it may still be <font color="blue">difficult</font> to     <font color="blue">convince hospitals</font> and other <font color="blue">health care providers</font> to offer the <font color="blue">Stretta     </font>procedure  to  their patients</td>
    </tr>
    <tr>
      <td>Some <font color="blue">private payers may refuse adequate</font>     <font color="blue">reimbursement</font> even though <font color="blue">significant</font> peer-reviewed data has <font color="blue">been published</font></td>
    </tr>
    <tr>
      <td>If users of our <font color="blue">products cannot</font> obtain sufficient <font color="blue">reimbursement</font> from health     <font color="blue">care payers</font> for the Stretta procedure or the <font color="blue">Stretta System </font><font color="blue">disposables</font>,     then it is unlikely that our <font color="blue"><font color="blue">products will</font> ever</font> achieve <font color="blue">increased market</font>     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________       <font color="blue">Although the Secca </font>procedure has <font color="blue">been awarded</font> an APC code by the CMS, it has     not  received  a  CPT  code and there is little data yet regarding the     <font color="blue">willingness</font> of third-party health <font color="blue">care payers</font> to reimburse the costs of the     procedure</td>
    </tr>
    <tr>
      <td>While we believe that a Level 1CPT code will be issued for the     Secca <font color="blue">procedure <font color="blue">effective</font> either from</font> January 1, 2007, or January 1, 2008,     <font color="blue">depending upon</font> the timing of meeting of the <font color="blue">necessary</font> pre-conditions we     <font color="blue">cannot assure</font> you that the <font color="blue">procedure will ever</font> be reimbursed, or that in the     <font color="blue">event there</font> is <font color="blue">reimbursement</font>, that such <font color="blue">reimbursement</font> will be adequate</td>
    </tr>
    <tr>
      <td>Failure to achieve adequate <font color="blue">reimbursement</font> may have a serious negative effect     on our ability to grow our revenues</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement  </font>from third-party health <font color="blue">care payers</font> is <font color="blue">uncertain due</font> to     <font color="blue">factors beyond</font> our control and changes in third-party health <font color="blue">care payers</font>’     <font color="blue">policies could <font color="blue">adversely</font> affect</font> our <font color="blue">sales growth</font></td>
    </tr>
    <tr>
      <td>Even if third-party payers provide adequate <font color="blue">reimbursement</font> for the <font color="blue">Stretta     </font>procedure,  adverse  changes  in  third-party  payers’ policies toward     <font color="blue">reimbursement</font> could preclude market <font color="blue">acceptance</font> for our products and have a     material adverse effect on our sales and <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>We are unable to     predict what changes will be made in the <font color="blue">reimbursement</font> methods used by     third-party health <font color="blue">care payers</font></td>
    </tr>
    <tr>
      <td>For example, some health <font color="blue">care payers</font> are moving toward a <font color="blue">managed care system</font>     in <font color="blue">which providers contract</font> to <font color="blue">provide comprehensive health care</font> for a fixed     cost per person</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that in a <font color="blue">prospective payment system</font>,     which is used in many <font color="blue">managed care system</font>s, the cost of our <font color="blue">products will</font> be     <font color="blue"><font color="blue">incorporated</font> into</font> the <font color="blue">overall payment</font> for the procedure or that <font color="blue">there will</font>     be adequate <font color="blue">reimbursement</font> for our products separate from <font color="blue">reimbursement</font> for     the procedure</td>
    </tr>
    <tr>
      <td>Internationally, market <font color="blue">acceptance</font> of our <font color="blue">products will</font> be <font color="blue">dependent upon</font>     the <font color="blue">availability</font> of adequate <font color="blue">reimbursement</font> within prevailing health care     payment  systems</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement  </font>and  health  care payment systems in     <font color="blue">international</font>  markets  vary <font color="blue"><font color="blue">significant</font>ly</font> by country and include both     government-sponsored health care and private insurance</td>
    </tr>
    <tr>
      <td>Although we are     seeking <font color="blue">international</font> <font color="blue">reimbursement</font> approvals, we <font color="blue">cannot assure</font> you that any     <font color="blue"><font color="blue">such approvals</font> will</font> be obtained in a <font color="blue">timely manner</font> or at all</td>
    </tr>
    <tr>
      <td>If foreign     third-party payers do not <font color="blue"><font color="blue">adequately</font> reimburse providers</font> for the <font color="blue">Stretta     </font>procedure and the <font color="blue">products used with</font> it, then our sales and <font color="blue">revenue growth</font>     may be limited</td>
    </tr>
    <tr>
      <td>If physicians do not adopt our products, we will not achieve <font color="blue">future sales</font>     growth</td>
    </tr>
    <tr>
      <td>To achieve <font color="blue">increasing sales</font>, our <font color="blue">products must continue</font> to <font color="blue">gain recognition</font>     and  adoption  <font color="blue">by physicians</font> who <font color="blue">treat gastrointestinal disorders</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">products represent</font> a <font color="blue">significant</font> departure from <font color="blue">conventional</font> treatment     methods</td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">physicians will</font> not <font color="blue">increase rates</font> of adoption of     our <font color="blue">systems unless</font> they determine, based on published peer-reviewed journal     articles, long-term clinical data and their <font color="blue">professional</font> experience, that     our <font color="blue">systems provide</font> an <font color="blue">effective</font> and <font color="blue">attractive alternative</font> to <font color="blue">conventional</font>     means of treatment</td>
    </tr>
    <tr>
      <td>Currently, there are over 30 peer-reviewed journal     <font color="blue">articles on</font> the Stretta procedure, including the results of our <font color="blue">Stretta     </font>randomized  trial, and six peer-reviewed journal <font color="blue">articles on</font> the <font color="blue">Secca     </font>procedure</td>
    </tr>
    <tr>
      <td>Some <font color="blue">physicians also may</font> be slow to adopt our products because of     perceived <font color="blue"><font color="blue">liability</font> risks</font> and <font color="blue">inadequacy</font> of third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">adverse events</font> or recalls could also impact future <font color="blue">acceptance</font> rates</td>
    </tr>
    <tr>
      <td>Additionally, some of our customers and <font color="blue">potential customers also find</font> the     30-45 minutes <font color="blue">necessary</font> to perform a Stretta procedure to be a limiting     issue, as their <font color="blue">endoscopy</font> unit schedule is <font color="blue">typically dominated by</font> short     <font color="blue">diagnostic procedures</font></td>
    </tr>
    <tr>
      <td>If we cannot achieve <font color="blue">increasing physician adoption</font>     rates  of  our  products, we may never achieve <font color="blue"><font color="blue">significant</font> revenues</font> or     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If  the  <font color="blue"><font color="blue">effective</font>ness</font> and safety of our products are not supported by     long-term  data,  our  sales  could decline and we could be subject to     <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We received <font color="blue">clearance from</font> the FDA for the use of the <font color="blue">Secca System </font>to treat     bowel  <font color="blue">incontinence</font>,  for  patients  who have failed more <font color="blue">conservative</font>     <font color="blue">treatments</font> such as diet <font color="blue">modification</font> or biofeedback</td>
    </tr>
    <tr>
      <td>This clearance was     <font color="blue">based upon</font> the study of 50 patients</td>
    </tr>
    <tr>
      <td>Safety and efficacy data presented to     the FDA for the <font color="blue">Secca System </font>was                                           18     ______________________________________________________________________       based  on  six-month  follow-up studies on these patients</td>
    </tr>
    <tr>
      <td>However, if     longer-term <font color="blue">patient studies</font> or clinical experience indicate that treatment     with the <font color="blue">Secca System </font>does not <font color="blue">provide patients with sustained benefits</font> or     that <font color="blue">treatment with</font> our product is less <font color="blue">effective</font> or <font color="blue">less safe than</font> our     <font color="blue">current data</font> suggests, our <font color="blue"><font color="blue">sales could</font> decline</font> and we could be subject to     <font color="blue">significant</font>  <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Further,  we  may  find  that our data is not     <font color="blue">substantiated</font> in <font color="blue">studies involving</font> more patients, in which case we may never     achieve  <font color="blue">significant</font>  revenues or <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">patient studies</font> or     clinical experience do not meet our <font color="blue">expectations</font> regarding the benefits of     the  Secca  System,  our expected <font color="blue">revenues from</font> this <font color="blue">product may never</font>     <font color="blue">materialize</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>in our physician <font color="blue">education</font> efforts could <font color="blue"><font color="blue">significant</font>ly</font> reduce     <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>It is important to the success of our <font color="blue">sales efforts</font> to <font color="blue">educate physicians</font> in     the <font color="blue">techniques</font> of using our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on physicians</font> to spend their     time and money to attend pre-sale <font color="blue">education</font>al sessions</td>
    </tr>
    <tr>
      <td>Positive results     using  the  Stretta and Secca Systems are highly <font color="blue">dependent upon</font> proper     <font color="blue">physician technique</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">physicians use either system improperly</font>, they may     have unsatisfactory <font color="blue">patient outcomes</font> or cause patient injury, which may give     rise to <font color="blue">negative publicity</font> or <font color="blue">lawsuits <font color="blue">against us</font></font>, any of <font color="blue">which could</font> have a     material adverse effect on our sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We  face  <font color="blue">competition</font>  from  more established GERD <font color="blue">treatments</font> and from     <font color="blue">competitors</font> with greater resources, which will make it <font color="blue">difficult</font> for us to     achieve <font color="blue">significant</font> market penetration</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>that have well-established products, reputations and resources     dominate the market for the treatment of GERD Our <font color="blue">primary <font color="blue">competitors</font></font> are     large medical device <font color="blue"><font color="blue">manufacture</font>r</font>s such as Ethicon Endo Surgery and United     States Surgical, <font color="blue"><font color="blue">manufacture</font>r</font>s of <font color="blue">instrumentation</font> for anti-reflux surgery     and  NDO  Surgical, which <font color="blue">manufacture</font>s an <font color="blue">endoscopic sewing</font> device for     treating GERD Other <font color="blue"><font color="blue">competitive</font> devices may</font> be developed</td>
    </tr>
    <tr>
      <td>Some  of  these  <font color="blue">competitors</font>  are  larger companies that enjoy several     <font color="blue">competitive</font> <font color="blue">advantages</font> over us, which may include:           •   Existing anti-reflux surgical procedures and devices for the treatment     of GERD;           •   <font color="blue">Established </font><font color="blue">reputations within</font> the surgical and <font color="blue">gastroenterological</font>     <font color="blue">community</font>;           •   <font color="blue">Established </font><font color="blue">distribution networks</font> that permit these companies to     <font color="blue">introduce <font color="blue">new products</font></font> and have <font color="blue">such products accepted by</font> the physician     <font color="blue">community</font> promptly;           •   <font color="blue">Established </font>relationships with <font color="blue">health care providers</font> and payers that     can be used to facilitate <font color="blue">reimbursement</font> for new <font color="blue">treatments</font>; and           •   Greater resources for <font color="blue">product <font color="blue">development</font></font> and sales and marketing</td>
    </tr>
    <tr>
      <td>We do not feel that we <font color="blue">compete with</font> large pharmaceutical companies, such as     AstraZeneca, Takeda Abbott Pharmaceutical, Wyeth Laboratories and Eisai,     because <font color="blue">candidate patients</font> for Stretta are intolerant to <font color="blue">drug therapy</font> or     have failed, or <font color="blue">only partially</font> responded to, <font color="blue">drug therapy</font></td>
    </tr>
    <tr>
      <td>However, these     companies  have  an <font color="blue">established <font color="blue">relationship with</font></font> the <font color="blue">gastroenterology</font>     <font color="blue">community</font> and generate over dlra12 billion in annual US <font color="blue">revenues from</font> the     <font color="blue">proton pump inhibitor drug</font> class</td>
    </tr>
    <tr>
      <td>We could be <font color="blue"><font color="blue">adversely</font> affected</font> if one or     more <font color="blue">pharmaceutical companies elects</font> to <font color="blue">market aggressively against</font> our     product, or if a new, more <font color="blue">effective</font>, pharmaceutical product is developed</td>
    </tr>
    <tr>
      <td>We have limited sales and <font color="blue">marketing resources</font>, and failure to manage our     <font color="blue">sales force</font> or to market and distribute our products <font color="blue"><font color="blue">effective</font>ly</font> will hurt     our revenues</td>
    </tr>
    <tr>
      <td>We  have limited sales and <font color="blue">marketing resources</font></td>
    </tr>
    <tr>
      <td><font color="blue">Currently </font>we rely on a     limited number of <font color="blue">direct sales representatives</font> for the sale of our products     in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also deploy</font> an indirect sales channel of a limited     number  of <font color="blue"><font color="blue">manufacture</font>r</font>s representatives firms who we use to cover, in     general, less populated areas of                                           19     ______________________________________________________________________       the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The success of this <font color="blue">channel will depend upon</font> a number of     factors, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>These factors include, but     are not limited to, the <font color="blue">willingness</font> of <font color="blue">such representatives</font> to prioritize     the sale of our products and their <font color="blue"><font color="blue">effective</font>ness</font> in such <font color="blue">sales efforts</font></td>
    </tr>
    <tr>
      <td>There are <font color="blue">significant</font> risks involved in building and managing our sales     force and marketing our products, including our:           •   <font color="blue">Inability </font>to gain market <font color="blue">acceptance</font> of our products and <font color="blue">technology</font>;           •   <font color="blue">Inability </font>to hire a sufficient number of qualified sales people with     the skills and understanding to sell the Stretta and Secca Systems     <font color="blue"><font color="blue">effective</font>ly</font>;           •   Failure to <font color="blue">adequately</font> train our <font color="blue">sales force</font> in the use and benefits of     our products, making them less <font color="blue">effective</font> promoters; and           •   Failure to <font color="blue">accurately</font> price our products as <font color="blue">attractive alternative</font>s to     <font color="blue">conventional</font> <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">adequately</font> address these <font color="blue">risks will harm</font> our ability to sell     our products</td>
    </tr>
    <tr>
      <td>Internationally, we rely on third-party <font color="blue">distributors</font> to sell our products,     and we <font color="blue">cannot assure</font> you that these <font color="blue"><font color="blue">distributors</font> will commit</font> the <font color="blue">necessary</font>     resources to <font color="blue"><font color="blue">effective</font>ly</font> market and sell our products</td>
    </tr>
    <tr>
      <td>Internationally, we rely on a network of <font color="blue">distributors</font> to sell our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> these <font color="blue">distributors</font> in <font color="blue">such markets</font> and we will need to attract     <font color="blue">additional</font> <font color="blue">distributors</font> to grow our business and expand the <font color="blue">territories into</font>     which  we sell our products</td>
    </tr>
    <tr>
      <td><font color="blue">Distributors </font>may not commit the <font color="blue">necessary</font>     resources to market and sell our products to the level of our <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>If current or future <font color="blue">distributors</font> do not perform <font color="blue">adequately</font>, we may not     realize expected <font color="blue">international</font> <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> the suppliers who provide the materials and <font color="blue"><font color="blue">components</font> used</font> in     our products, and if we lose our <font color="blue">relationship with</font> any individual suppliers,     we will face <font color="blue">regulatory</font> <font color="blue">requirement</font>s with regard to <font color="blue">replacement</font> suppliers     that <font color="blue">could delay</font> the <font color="blue">manufacture</font> of our products</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">suppliers provide materials</font> and <font color="blue"><font color="blue">components</font> used</font> in our products,     some of which are the single and/or sole source for the <font color="blue">components</font> they     provide</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">suppliers become unwilling</font> or unable to supply us     with our <font color="blue">requirement</font>s, <font color="blue">replacement</font> or <font color="blue">alternative sources might</font> not be     readily  obtainable  due  to <font color="blue">regulatory</font> <font color="blue">requirement</font>s applicable to our     <font color="blue">manufacturing</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font><font color="blue">components</font> from a new supplier may     require a new or supplemental filing with applicable <font color="blue">regulatory</font> authorities     and clearance or approval of the filing before we <font color="blue">could resume product</font>     sales</td>
    </tr>
    <tr>
      <td>This <font color="blue">process may</font> take a substantial period of time, and we cannot     assure  you  that  we would be able to obtain the <font color="blue">necessary</font> <font color="blue">regulatory</font>     clearance or approval</td>
    </tr>
    <tr>
      <td>This could create <font color="blue">supply disruptions</font> that would     reduce our <font color="blue">product sales</font> and revenue</td>
    </tr>
    <tr>
      <td>If  we,  or  our suppliers, fail to <font color="blue">comply with</font> the FDA Quality System     Regulation, <font color="blue">manufacturing</font> <font color="blue">operations</font> could be delayed and our business could     be harmed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> processes are required to <font color="blue">comply with</font> the Quality System     Regulation,  or QSR, <font color="blue">which covers</font> the methods and <font color="blue">documentation</font> of the     design, testing, production, control, quality assurance, labeling, packaging     and shipping of our products</td>
    </tr>
    <tr>
      <td>The FDA enforces the QSR <font color="blue">through <font color="blue">inspections</font></font></td>
    </tr>
    <tr>
      <td>There were no <font color="blue">significant</font> findings from either inspection</td>
    </tr>
    <tr>
      <td>If we     fail any future QSR <font color="blue">inspections</font>, our <font color="blue">operations</font> could be disrupted and our     <font color="blue">manufacturing</font> delayed</td>
    </tr>
    <tr>
      <td>Failure to take <font color="blue">appropriate</font> corrective action in     response <font color="blue">to a QSR </font><font color="blue">inspection could force</font> a shut-down of our <font color="blue">manufacturing</font>     <font color="blue">operations</font>, a recall of our products, and <font color="blue">potentially</font> a revocation of the     FDA 510(k) clearance of our products, <font color="blue">which would</font> have a material adverse     effect on our <font color="blue">product sales</font>, revenues, expected revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Furthermore, we <font color="blue">cannot assure</font> you that our key component suppliers are, or     will continue to be, in <font color="blue">compliance with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirement</font>s,     will  not encounter any <font color="blue">manufacturing</font> <font color="blue">difficult</font>ies, or will be able to     maintain <font color="blue">compliance with</font> <font color="blue">regulatory</font> <font color="blue">requirement</font>s</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such event could</font> have     a material adverse effect on our <font color="blue">available inventory</font> and <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       Our failure to obtain or maintain <font color="blue">necessary</font> FDA <font color="blue">clearances</font> or approvals     <font color="blue">could hurt</font> our ability to <font color="blue"><font color="blue">commercially</font> distribute</font> and market our products in     the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">medical devices</font> and are therefore subject to extensive     regulation in the <font color="blue">United States</font> and in <font color="blue">foreign countries</font> where we intend to     do business</td>
    </tr>
    <tr>
      <td>Unless an exemption applies, each new <font color="blue">Class II or III </font>medical     device that we wish to market in the <font color="blue">United States</font> must first receive either     510(k) clearance or <font color="blue"><font color="blue">premarket approval</font> from</font> the FDA Either process can be     lengthy and expensive</td>
    </tr>
    <tr>
      <td>The FDA’s 510(k) clearance process usually takes from     four to twelve months, but may take longer</td>
    </tr>
    <tr>
      <td>The <font color="blue">premarket application</font>, or     PMA,  approval  process is much more costly, lengthy and uncertain</td>
    </tr>
    <tr>
      <td>It     <font color="blue">generally</font> takes from one to <font color="blue">three years</font> or <font color="blue">even longer</font></td>
    </tr>
    <tr>
      <td>Delays in obtaining     <font color="blue">regulatory</font>  clearance or approval will <font color="blue">adversely</font> affect our ability to     <font color="blue">generate revenue</font>s and <font color="blue">profitability</font> from <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that the FDA will ever grant 510(k) clearance or <font color="blue">premarket approval</font> for any     new product we propose to market</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>withdraws or refuses to grant     approvals, we will be unable to <font color="blue">market such products</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If we market our products for uses that the FDA has not approved, we could     be subject to FDA <font color="blue"><font color="blue">enforcement</font> action</font></td>
    </tr>
    <tr>
      <td>Our Stretta and Secca Systems are <font color="blue">cleared by</font> the FDA, the <font color="blue">Stretta System </font>for     the  treatment of GERD and the <font color="blue">Secca System </font>for the treatment of bowel     <font color="blue">incontinence</font> in patients who have failed more <font color="blue">conservative</font> therapies such as     diet  <font color="blue">modification</font>  and  biofeedback</td>
    </tr>
    <tr>
      <td>FDA <font color="blue">regulations prohibit us from</font>     promoting or <font color="blue">advertising either system</font>, or any <font color="blue">future cleared</font> or approved     devices, for uses not within the scope of our <font color="blue">clearances</font> or approvals</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue">de<font color="blue">termination</font></font>s</font>  can  be  subjective, and the FDA <font color="blue">may disagree with</font> our     promotional claims</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>requires us to revise our promotional claims     or  takes  <font color="blue">enforcement</font>  action  <font color="blue">against us</font> <font color="blue">based upon</font> our labeling and     <font color="blue">promotional materials</font>, our <font color="blue">sales could</font> be delayed, our <font color="blue">profitability</font> could     be harmed and we could be required to pay <font color="blue">significant</font> fines or penalties</td>
    </tr>
    <tr>
      <td><font color="blue">Modifications </font>to our marketed devices may require new 510(k) <font color="blue">clearances</font> or     PMA  approvals or require us to <font color="blue">cease marketing</font> or recall the modified     devices until such <font color="blue">clearances</font> are obtained</td>
    </tr>
    <tr>
      <td>Any <font color="blue">modification</font> to an FDA 510(k)-cleared device that could <font color="blue"><font color="blue">significant</font>ly</font>     affect its safety or <font color="blue"><font color="blue">effective</font>ness</font>, or that <font color="blue">would constitute</font> a major change     in its <font color="blue">intended use</font>, requires a new FDA 510(k) clearance or, possibly, PMA     approval</td>
    </tr>
    <tr>
      <td>The FDA requires every <font color="blue"><font color="blue">manufacture</font>r</font> to make this <font color="blue">de<font color="blue">termination</font></font> in     the  first instance, but the FDA can review any <font color="blue">such decision</font></td>
    </tr>
    <tr>
      <td>We have     <font color="blue">modified aspects</font> of our products, but we believe that new 510(k) <font color="blue">clearances</font>     are not required</td>
    </tr>
    <tr>
      <td>We may modify future products after they have received     clearance or approval, and, in <font color="blue">appropriate</font> <font color="blue">circumstances</font>, we may determine     that new clearance or approval is un<font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>Though we believe these     changes <font color="blue">fall within</font> the acceptable scope of changes allowed for <font color="blue">Class II     </font>devices, we <font color="blue">cannot assure</font> you that the FDA <font color="blue">would agree with</font> any of our     <font color="blue">decisions</font> not to <font color="blue">seek new clearance</font> or approval</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>requires us to     seek 510(k) clearance or PMA approval for any <font color="blue">modification</font> to a <font color="blue">previously</font>     <font color="blue">cleared product</font>, we also may be required to <font color="blue">cease marketing</font> or recall the     modified device until we obtain <font color="blue">such clearance</font> or approval</td>
    </tr>
    <tr>
      <td>Also, in such     <font color="blue">circumstances</font>,  we  may  be subject to <font color="blue">significant</font> <font color="blue">regulatory</font> fines or     penalties</td>
    </tr>
    <tr>
      <td>We <font color="blue">face risks</font> related to our <font color="blue">international</font> <font color="blue">operations</font>, including the need to     obtain <font color="blue">necessary</font> foreign <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>To date we have <font color="blue">international</font> distribution agreements for <font color="blue">various countries</font>     around the world</td>
    </tr>
    <tr>
      <td>While we have obtained <font color="blue">regulatory</font> clearance to market the     Stretta and Secca Systems in some of the countries, or others <font color="blue">regulatory</font>     approval is pending</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to obtain or     maintain <font color="blue">such approvals</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">although contracts already signed with</font>     European <font color="blue">distributors</font> specify payment in US dollars, future <font color="blue">international</font>     sales may be made in currencies other than the US dollar</td>
    </tr>
    <tr>
      <td>As a result,     currency <font color="blue">fluctuations</font> may impact the demand for our products in countries     where the US dollar has <font color="blue">increased compared</font> to the <font color="blue">local currency</font></td>
    </tr>
    <tr>
      <td><font color="blue">Engaging     </font>in <font color="blue">international</font> business involves the following <font color="blue">additional</font> risks:           •   Export <font color="blue">restrictions</font>, tariff and <font color="blue">trade regulations</font>, and <font color="blue">foreign tax</font>     laws;           •   Customs duties, export quotas or other trade <font color="blue">restrictions</font>;                                           21     ______________________________________________________________________         •   Economic or political <font color="blue">instability</font>;           •   Shipping delays; and           •   Longer <font color="blue">payment cycles</font></td>
    </tr>
    <tr>
      <td>In addition, contracts may be <font color="blue">difficult</font> to enforce and receivables <font color="blue">difficult</font>     to <font color="blue">collect through</font> a foreign country’s legal system, and the protection of     <font color="blue"><font color="blue">intellectual</font> property</font> in <font color="blue">foreign countries</font> may be more <font color="blue">difficult</font> to enforce</td>
    </tr>
    <tr>
      <td>Any of these factors could cause our <font color="blue">international</font> sales to decline, which     would impact our expected sales and growth rates</td>
    </tr>
    <tr>
      <td><font color="blue">Product  </font><font color="blue">liability</font>  suits  against  us  may  result  in  expensive and     time-consuming <font color="blue">litigation</font>, payment of substantial damages and an increase in     our <font color="blue">insurance rates</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">development</font>,  <font color="blue">manufacture</font> and sale of <font color="blue">medical products involves</font> a     <font color="blue">significant</font> risk of product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>The use of any of our products     <font color="blue">may expose us</font> to <font color="blue">liability</font> claims, <font color="blue">which could</font> divert <font color="blue">management</font>’s attention     from our core business, could be expensive to defend, and could result in     substantial <font color="blue">damage awards <font color="blue">against us</font></font></td>
    </tr>
    <tr>
      <td>For example, we are currently a party     to a product <font color="blue">liability</font> lawsuit where there are <font color="blue">allegations</font> that our products     are <font color="blue">defectively designed</font> and that we were negligent in <font color="blue">manufacturing</font> our     products</td>
    </tr>
    <tr>
      <td>We maintain product <font color="blue">liability</font> insurance at coverage levels we believe to be     <font color="blue">commercially</font> acceptable, and we re-evaluate annually whether we need to     obtain <font color="blue">additional</font> product <font color="blue">liability</font> insurance</td>
    </tr>
    <tr>
      <td>However there can be no     assurance  that product <font color="blue">liability</font> or other claims will not <font color="blue">exceed such</font>     insurance  coverage  limits or that <font color="blue">such insurance will continue</font> to be     <font color="blue">available on</font> the same or <font color="blue">substantially</font> similar terms, or at all</td>
    </tr>
    <tr>
      <td>We  have  limited  protection  for  our  <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>If our     <font color="blue"><font color="blue">intellectual</font> property</font> does not <font color="blue">sufficiently protect</font> our products, third     parties  will  be  able  to  <font color="blue">compete <font color="blue">against us</font></font> more directly and more     <font color="blue"><font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>We rely on patent, copyright, trade secret and <font color="blue">trademark laws</font> to protect our     products, including our Stretta Catheter, our <font color="blue">Secca Handpiece </font>and our Curon     Control Module, from being duplicated by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>However, these laws     <font color="blue">afford only</font> limited protection</td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent <font color="blue">applications</font></font> and the notices of     allowance we have received may not issue as patents or, if issued, may not     issue in a form that will be <font color="blue">advantageous</font> to us</td>
    </tr>
    <tr>
      <td>Patents we have obtained     and may obtain in the <font color="blue">future may</font> be challenged, invalidated or legally     <font color="blue">circumvented</font>  by  third  parties</td>
    </tr>
    <tr>
      <td>We  may  not be able to prevent the     unauthorized <font color="blue">disclosure</font> or use of our <font color="blue">technical knowledge</font> or other trade     secrets by consultants, vendors, former employees or <font color="blue">current employees</font>,     despite the existence of non<font color="blue">disclosure</font> and <font color="blue">confidentiality agreements</font> and     other contractual <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>Furthermore, the laws of <font color="blue">foreign countries</font>     may not protect our <font color="blue"><font color="blue">intellectual</font> property</font> rights to the <font color="blue">same extent as</font> the     laws  of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">intellectual</font> property</font> rights do not     <font color="blue">adequately</font> protect our <font color="blue">commercial products</font>, our <font color="blue">competitors</font> could develop     <font color="blue">new products</font> or <font color="blue">enhance existing products</font> to compete more directly and     <font color="blue"><font color="blue">effective</font>ly</font> with us and harm our <font color="blue">product sales</font> and <font color="blue">market position</font></td>
    </tr>
    <tr>
      <td>Because, in the <font color="blue">United States</font>, <font color="blue">patent <font color="blue">applications</font></font> are <font color="blue">secret unless</font> and     <font color="blue">until issued as patents</font>, or <font color="blue">corresponding <font color="blue">applications</font></font> are published in     other countries, and because <font color="blue">publication</font> of <font color="blue">discoveries</font> in the scientific or     patent literature often lags behind actual <font color="blue">discoveries</font>, we cannot be certain     that we were the first to file <font color="blue">patent <font color="blue">applications</font></font> for <font color="blue">such inventions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>or <font color="blue">regulatory</font> <font color="blue">proceedings</font>, <font color="blue">which could</font> result in substantial cost     and  <font color="blue">uncertainty</font>,  may  also  be  <font color="blue">necessary</font> to enforce patent or other     <font color="blue"><font color="blue">intellectual</font> property</font> rights or to determine the scope and validity of other     parties’ <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will have the     <font color="blue">financial resources</font> to defend our <font color="blue">patents from infringement</font> or claims of     <font color="blue">invalidity</font></td>
    </tr>
    <tr>
      <td>Because of our <font color="blue">reliance on</font> unique <font color="blue">technology</font> to develop and <font color="blue">manufacture</font>     innovative products, we <font color="blue">depend on</font> our ability to operate without infringing     or <font color="blue">misappropriating</font> the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>There  is  a  substantial  amount  of <font color="blue"><font color="blue">litigation</font> over patent</font> and other     <font color="blue"><font color="blue">intellectual</font> property</font> rights in the medical device industry</td>
    </tr>
    <tr>
      <td>Because we rely     on unique <font color="blue">technology</font> to develop and <font color="blue">manufacture</font> innovative products, we are                                           22     ______________________________________________________________________       <font color="blue">especially sensitive</font> to the risk of infringing <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>While  we  attempt  to  ensure that our products do not infringe other     parties’ patents and <font color="blue">proprietary</font> rights, our <font color="blue">competitors</font> may assert that our     products and the methods they <font color="blue">employ may</font> be <font color="blue">covered by patents</font> held by them     or <font color="blue">invented by them</font> before they were <font color="blue">invented by us</font></td>
    </tr>
    <tr>
      <td>Although we may seek to     obtain a license or other <font color="blue">agreement under</font> a third party’s <font color="blue">intellectual</font>     property  rights to bring an end to certain claims or actions asserted     <font color="blue">against us</font>, we may not be able to obtain such an <font color="blue">agreement on reasonable</font>     terms  or  at all</td>
    </tr>
    <tr>
      <td>If we were not successful in obtaining a license or     <font color="blue">redesigning</font> our products, our <font color="blue">product sales</font> and <font color="blue">profitability</font> could suffer,     and we could be subject to <font color="blue">litigation</font> and <font color="blue">potentially</font> substantial damage     awards</td>
    </tr>
    <tr>
      <td>Also, one or more of our <font color="blue">products may</font> now be <font color="blue">infringing inadvertently on</font>     <font color="blue">existing patents</font></td>
    </tr>
    <tr>
      <td>As the number of <font color="blue">competitors</font> in our markets grows, the     <font color="blue">possibility</font> of a <font color="blue">patent infringement</font> claim <font color="blue">against us</font> increases</td>
    </tr>
    <tr>
      <td>Whether a     product infringes a patent involves complex legal and factual issues, the     <font color="blue">de<font color="blue">termination</font></font>  of  which  is  often  uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Infringement </font>and other     <font color="blue"><font color="blue">intellectual</font> property</font> claims, with or <font color="blue">without merit</font>, can be expensive and     time-consuming to litigate and divert <font color="blue">management</font>’s attention from our core     business</td>
    </tr>
    <tr>
      <td>If we lose in this kind of <font color="blue">litigation</font>, a <font color="blue">court could</font> require us to     pay substantial damages or <font color="blue">grant royalties</font>, and <font color="blue">prohibit us from using</font>     <font color="blue">technologies essential</font> to our products</td>
    </tr>
    <tr>
      <td>This kind of <font color="blue">litigation</font> is expensive     to  all  parties  and  consumes large amounts of <font color="blue">management</font>’s time and     attention</td>
    </tr>
    <tr>
      <td>In addition, because <font color="blue">patent <font color="blue">applications</font></font> can take many years to     issue, there may be <font color="blue">applications</font> now pending of which we are unaware and     <font color="blue">which may later</font> result in <font color="blue">issued patents</font> that our <font color="blue">products may</font> infringe</td>
    </tr>
    <tr>
      <td>If we lose our rights to <font color="blue"><font color="blue">intellectual</font> property</font> that we have licensed we may     be forced to develop new <font color="blue">technology</font> and we may not be able to develop that     <font color="blue">technology</font> or may experience delays in <font color="blue">manufacturing</font> as a result</td>
    </tr>
    <tr>
      <td>Our <font color="blue">license with</font> Gyrus Group PLC, a public company <font color="blue">incorporated</font> and existing     under the laws of England and Wales, <font color="blue">allows us</font> to <font color="blue">manufacture</font> and sell our     <font color="blue">products using</font> their radiofrequency generator <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">University of Kansas </font>license <font color="blue">allows us</font> to <font color="blue">apply radiofrequency energy</font> to     tissue</td>
    </tr>
    <tr>
      <td>To the extent these license interests become <font color="blue">jeopardized</font> through     <font color="blue">termination</font> or material breach of the <font color="blue">license agreements</font>, our <font color="blue">operations</font> may     be  harmed</td>
    </tr>
    <tr>
      <td>We  may  have  to develop new <font color="blue">technology</font> or license other     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot provide</font> any assurance that we will be able to develop     such <font color="blue">technology</font> or that other <font color="blue">technology</font> will be available for license</td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font>if  such  <font color="blue">technology</font>  is  available,  we  may experience delays in our     <font color="blue">manufacturing</font> as we transition to a different <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">stockholder rights</font> plan, <font color="blue">certificate</font> of incorporation, bylaws and     <font color="blue">Delaware </font><font color="blue">law contain provisions</font> that <font color="blue">could discourage</font> a takeover</td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2001, we adopted a <font color="blue">stockholder rights</font> plan</td>
    </tr>
    <tr>
      <td>The purpose of the     plan is to <font color="blue">assure fair value</font> in the event of a <font color="blue">future unsolicited</font> business     <font color="blue">combination</font> or similar <font color="blue">transaction involving</font> Curon</td>
    </tr>
    <tr>
      <td>If an individual or     entity <font color="blue">accumulates</font> 15prca of our stock, or 20prca in the case of <font color="blue">certain existing</font>     <font color="blue">stockholders</font>, the <font color="blue">rights become exercisable</font> for <font color="blue">additional</font> shares of our     <font color="blue">common stock</font> or, if <font color="blue">followed by</font> a merger or other business <font color="blue">combination</font> where     Curon does not survive, <font color="blue">additional</font> shares of the acquirer’s <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The intent of these rights is to force a <font color="blue">potential acquirer</font> to negotiate     with  the  Board to increase the <font color="blue">consideration</font> paid for our stock</td>
    </tr>
    <tr>
      <td>The     existence of this plan, however, may deter a <font color="blue">potential acquirer</font>, <font color="blue">which could</font>     <font color="blue">negatively</font> impact shareholder value</td>
    </tr>
    <tr>
      <td>In  addition,  our  <font color="blue">basic corporate documents</font> and <font color="blue">Delaware </font>law contain     provisions that <font color="blue">might enable</font> our <font color="blue">management</font> to resist a takeover</td>
    </tr>
    <tr>
      <td>Any of the     above provisions might discourage, delay or prevent a change in the control     of  our  company or a change in our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>The existence of these     provisions could <font color="blue">adversely</font> affect the <font color="blue">voting power</font> of holders of common     stock and limit the price that <font color="blue">investors might</font> be willing to pay in the     future for shares of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>